Akebia Therapeutics, Inc. Share Price & Technical Analysis
AKBA · $1.06 (+3.92%)
Healthcare / Drug Manufacturers - Specialty & Generic
$1.06
+3.92%
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and A…
Price chart
Seasonality
May has 2 positive and 2 negative years (last 5 years shown)
-29% return in May, 9% avg return in past 3 year May month.
-41% return in 2026, 64% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -12% | -7% | 8% | 0% | -29% | – | – | – | – | – | – | – | -41% |
| 25 | 16% | -14% | 0% | 20% | 25% | 16% | 3% | -16% | -13% | -19% | -27% | 0% | -9% |
| 24 | 42% | -6% | 13% | -32% | -8% | -9% | 40% | 7% | -13% | 31% | 24% | -10% | 78% |
| 23 | 0% | 33% | -25% | 50% | 11% | -10% | 89% | -18% | -21% | -18% | 22% | 9% | 122% |
| 22 | -13% | 10% | -70% | -43% | 0% | 0% | -20% | 0% | -25% | 0% | 0% | 100% | -60% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Weak
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090, which is in Phase 2 clinical trial for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries; Vafseo License and Collaboration Agreements; CSL Vifor Agreements; Averoa License Agreement; License Agreement with Panion & BF Biotech, Inc.; Cyclerion Therapeutics License Agreement; and Q32 Asset Purchase Agreement. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$315.20M
P/E ratio
—
52W high
$4.08
52W low
$0.88
Volume
10,33,500
Beta
0.35
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Akebia Therapeutics, Inc. share price today?
- Akebia Therapeutics, Inc. (AKBA) last traded around $1.06 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does AKBA have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for AKBA. Download the app for real-time alerts.
- How can I analyze Akebia Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.